Target
Bruton tyrosine kinase (BTK)
12 abstracts
Abstract
A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.Org: Willamette Valley Cancer Institute and Reserach Center, US Oncology Hematology Research Program, US Oncology Research and Rocky Mountain Cancer Centers,
Abstract
Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi.Org: Wilmington, PINC AI Applied Sciences,
Abstract
BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom, Haematology Unit, Bnai Zion Medical Center, Haifa, Israel, Department of Hematology & BMT, Chaim Sheba Medical Center, Tel Aviv, Israel, Summit Cancer Center, Spok, WA, Hadassah Medical Center, Jerusalem, Israel,
Abstract
BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Org: Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,
Abstract
Risk of hypertension in patients with CLL/SLL who participated in ALPINE: A post hoc analysis.Org: BeiGene, Ltd, Cardiology Center, University of Connecticut Health Center,
Abstract
Real-world understanding of the unmet need for treatment of non-covalent BTKi in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ,
Abstract
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.Org: UCI Health, Medical College of Wisconsin, Maria Sklodowska-Curie National Research Institute of Oncology, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Linear Clinical Research and Sir Charles Gairdner Hospital,
Abstract
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.Org: MD Anderson Cancer Center, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, University of British Columbia, Institut Curie, Saint Cloud, France, University of Bologna,
Abstract
BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Ohio State University Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, Sir Charles Gairdner Hospital, Loxo Oncology at Lilly, Eli Lilly and Company,
Abstract
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Department of Hematology and Cancer Prevention, Medical University of Silesia, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Memorial Sloan Kettering Cancer Center,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Abstract
Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.Org: Mount Sinai Hospital, University of Louisville, UPMC Harrisburg,